title: Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease.
abstract: Hepatitis B reactivation has been widely reported in patients undergoing immunosuppressive therapy in oncohaematological and transplant settings, with a high frequency of hepatic failure. This topic has received growing scientific interest and several studies reported the preventive effect of antiviral agents on hepatitis B reactivation during immunosuppression therapy. Routine prophylaxis is therefore recommended and specific recommendations were elaborated by AASLD, EASL and AISF. On the contrary, few data are available on the risk of HBV reactivation in patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapy, and major questions regarding the optimal management (screening, prophylaxis, therapy, monitoring) of IBD patients with HBV infection remain to be addressed. The aim of this paper is to provide a systematic review of the literature to underline the main aspects of HBV infection and reactivation in patients affected by IBD treated with conventional or biological immunosuppressive drugs.
authors.affiliation: Department of Food Science, University of Naples Federico II, Italy. filomena.morisco@unina.it
authors.forename: Filomena
authors.initials: F
authors.lastname: Morisco
authors.forename: Fabiana
authors.initials: F
authors.lastname: Castiglione
authors.forename: Antonio
authors.initials: A
authors.lastname: Rispo
authors.forename: Tommaso
authors.initials: T
authors.lastname: Stroffolini
authors.forename: Roberto
authors.initials: R
authors.lastname: Vitale
authors.forename: Stefano
authors.initials: S
authors.lastname: Sansone
authors.forename: Rocco
authors.initials: R
authors.lastname: Granata
authors.forename: Ambrogio
authors.initials: A
authors.lastname: Orlando
authors.forename: Riccardo
authors.initials: R
authors.lastname: Marmo
authors.forename: Gabriele
authors.initials: G
authors.lastname: Riegler
authors.forename: Maurizio
authors.initials: M
authors.lastname: Vecchi
authors.forename: Livia
authors.initials: L
authors.lastname: Biancone
authors.forename: Nicola
authors.initials: N
authors.lastname: Caporaso
mesh_terms: D019072:Antibiotic Prophylaxis; D000998:Antiviral Agents / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy*; D015995:Prevalence; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents